MNMehwash Nadeem

Mehwash Nadeem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mehwash Nadeem has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Microaggressions, burnout and the ‘double burden’ in urology: An emerging workforce challenge

    by Hira Bakhtiar Khan, Mehwash Nadeem

    Burnout is an important concern within the urological workforce, with implications for trainee well-being, career satisfaction and workforce retention. UK studies have reported burnout rates among urology trainees ranging from 28.4% to 56%, with workload, rota gaps, limited protected training time and organisational culture identified as important contributors. However, these pressures may not be experienced equally by all clinicians. As the urological workforce becomes more diverse, attention should also be paid to workplace experiences that may compound existing occupational pressures. Microaggressions, stereotyping, exclusion, discrimination and reduced psychological safety may create additional psychosocial demands for some clinicians. We propose the concept of a ‘double burden’ to describe the potential interaction between the occupational demands of urological practice and these additional workplace pressures. This article considers the available evidence linking workplace culture, microaggressions and burnout, while acknowledging the current lack of robust urology-specific data. It highlights important research gaps and outlines practical approaches to improving psychological safety, inclusion and workforce well-being. Understanding not only the prevalence of burnout but also how workplace experiences are distributed across the workforce may be important in developing a more inclusive and sustainable future for UK urology.

  • Open Access

    UK urology trainee interest in functional urology: a national survey

    by James Liston, Pragnitha Chitteti, Sanad Saad, Magda Kujawa, Arun Sahai, Suzanne Biers, Mehwash Nadeem

  • Lower Urinary Tract Dysfunction in Renal Transplant Candidates: A Scoping Review of Assessment Methods and Post‐Transplant Urological Outcomes

    by Dhruv S. Sahni, David B. Kingsmore, Imran Ahmad, Mehwash Nadeem, Emma Aitken

    Purpose: We performed a scoping review to map the available evidence regarding pre‐transplant lower urinary tract dysfunction (LUTD) assessment in adult renal transplant candidates and to summarise reported associations between pre‐transplant LUTD and post‐transplant urological outcomes. Methods: Electronic databases were searched up to 30th September 2025. Studies were included if they assessed lower urinary tract function prior to kidney transplantation using clinical history, questionnaires or investigations and reported post‐transplant urological complications and/or graft outcomes. Risk of bias was assessed using ROBINS‐I V2 for comparative studies and QUIPS for prognostic studies. Owing to substantial clinical and methodological heterogeneity, findings were synthesised narratively. Results: A total of 11 studies comprising 4471 patients met the inclusion criteria. Assessment strategies varied considerably across studies, ranging from clinical history alone to validated symptom questionnaires, uroflowmetry and urodynamic testing. Six studies reported urinary tract infection (UTI) outcomes, with most suggesting an increased risk in patients with pre‐transplant LUTD. Evidence for acute urinary retention and urosepsis was limited but directionally consistent with higher complication rates. Data on graft survival outcomes were sparse and heterogeneous, with some studies suggesting an association between pre‐transplant LUTD and poorer graft survival. Conclusions: Pre‐transplant LUTD appears to be associated with an increased risk of post‐transplant urological complications, particularly UTIs. However, the evidence is heterogeneous and largely observational, predominantly derived from retrospective studies, with limited data on graft outcomes. This scoping review highlights marked heterogeneity in pre‐transplant LUTD assessment and supports the development of a standardised assessment framework to guide future research and clinical practice.


  • Open Access

    Treatment outcomes of multidisciplinary management of recurrent urinary tract infections: A 2‐year experience in a dedicated complex‐UTI clinic

    by Pragnitha Chitteti, Ekpeno Inyang, Ahmed Ghonaimy, Jayne Morris‐Laverick, Stephanie Bezemer, Igor Kubelka, Victoria McCune, Mehwash Nadeem

    Objectives: This work aimed to assess treatment outcomes in patients with recurrent urinary tract infections (rUTIs) managed in a dedicated multidisciplinary complex‐UTI clinic. In addition, this work aimed to evaluate the impact of tailored interventions on patient‐reported outcomes, including quality of life (QoL) and symptomatic improvement. Materials and Methods: A 2‐year, single‐centre, prospective observational cohort study was conducted in a dedicated tertiary care UTI clinic. A multidisciplinary team comprising urologists, microbiologists and specialist nurses developed individualized management plans based on thorough assessments, including patient history, physical examination and necessary investigations. Data variables included patient demographics, urine culture results with antibiotic sensitivities, investigations performed and the treatment options administered. The minimum follow‐up period was 6 months after the implementation of treatment in the clinic. Pretreatment and posttreatment QoL were assessed, along with posttreatment Patient Global Impression of Improvement (PGI‐I) scores. Results: A total of 211 patients (mean age: 58.3 years, 89.6% female) were included. First‐ and second‐line treatments were effective for 71% of patients, while 29% required tertiary interventions. Post‐treatment, 81% of patients reported good‐to‐excellent improvement on the PGI‐I scale, and 70% achieved good‐to‐excellent QoL. Overall treatment success, defined as reduced UTI frequency or symptom resolution, was reported in 87.7% of patients. Factors such as immunosuppression and history of hospital admission for urosepsis were associated with poor treatment outcomes with statistical significance. Conclusion: Dedicated multidisciplinary UTI clinics significantly improve treatment outcomes and QoL for patients with rUTIs. The findings support broader adoption of multidisciplinary approaches, emphasizing early intervention and tailored care to optimize clinical efficiency and enhance the patient experience.

  • Is Intravesical Gentamicin the New Gold Standard to Manage Refractory Urinary Tract Infections?—Experience From a Dedicated Multidisciplinary Complex UTI Clinic

    by Pragnitha Chitteti, Inyang Ekpeno, Jayne Morris‐Laverick, Stephanie Bezemer, Mehwash Nadeem

    Aims: To assess the effectiveness of intravesical gentamicin in managing recurrent urinary tract infections (rUTIs) refractory to first‐ and second‐line treatments.Methods and Materials: This single‐centre prospective cohort study included 41 patients treated with intravesical gentamicin over a 24‐month period from 2021 to 2023. A multidisciplinary team comprising functional urologists, microbiologists, and specialist nurses was involved in the decision‐making process and in designing the treatment protocol. Patients self‐administered gentamicin instillations into the bladder according to a 6‐month instillation schedule. Patients were followed up during and after the treatment period to assess the treatment response.Results: A total of 41 patients with rUTIs were treated using the 6‐month intravesical gentamicin regimen. Of these, 10 were male and 31 were female, with a mean age of 53 years. E. coli was isolated from urine cultures in 19 patients (46%), while 19 patients had multiple organisms. Serum gentamicin levels were undetectable in all patients 1 week after treatment initiation. The mean follow‐up period was 15 months with minimum follow up of 6 months for all patients. Following gentamicin administration, hospital admission rates due to urosepsis decreased from 46% to 5%, and the prevalence of multidrug‐resistant organisms in urine cultures decreased from 44% to 10%. A significant reduction in UTI frequency was observed in 80.5% of patients, with 71% reporting good to excellent Patient Global Impression of Improvement (PGI‐I) scores. Additionally, 76% of patients reported a significant improvement in Quality of Life (QoL).Conclusion: In our cohort of patients with recurrent and refractory UTIs, intravesical gentamicin instillations has shown to be both safe and effective, leading to notable improvements in patients’ symptoms and QoL.


  • Botulinum toxin A injection to the external urethral sphincter for voiding dysfunction in females: A tertiary center experience

    by Mehwash Nadeem, Jamie Lindsay, Mahreen Pakzad, Rizwan Hamid, Jeremy Ockrim, Tamsin Greenwell

    Aim: The aim of this study is to examine the functional outcomes of ona‐botulinum toxin A (BTX‐A) injection into the external urethral sphincter (EUS) for female patients with nonneurogenic nonrelaxing sphincter as the underlying cause of voiding dysfunction (VD).METHOD: A retrospective analysis was performed for all the patients with the urodynamic findings of higher than expected maximum urethral closure pressure (MUCP) who received their first injection during the study period. All patients were evaluated with preoperative videourodynamic study and urethral pressure profilometry and received 100 U of EUS BTX‐A. Patients aged less than 18 years and those with neurogenic bladder were excluded. All patients were followed up with the free flow, postvoid residuals (PVR), and patient global impression of improvement (PGI‐I) scale at 6 weeks and then at 3 monthly intervals.Result: We identified 35 female patients with a mean age of 37.5 ± 15 years (range 18–72 years) with a mean follow‐up of 20 months. More than 50% of patients had a history of prior surgical intervention and 28 (80%) patients were catheter dependent, a suprapubic catheterization, or clean intermittent self‐catheterization. Mean MUCP was 97.1 ± 22 cm of water. After treatment with BTX‐A, 21 (60%) patients were able to void per urethral (p = 0.02). The mean maximum flow rate (Qmax) improved from 8.8 to 11 mls/s and the mean PVR decreased from 200 to 149 mls (p < 0.05). On multivariate analysis, we identified high preoperative PVR, high preoperative actual MUCP, and previous surgical intervention (urethral dilatation, sacral neuromodulation, and pelvic surgery) as predictors of successful voiding restoration. The mean duration of response was 4.7 months, 46% of patients requested repeat injection, and 29% were established on maintenance injections. On the 5‐point PGI‐I score, 13 (37%), 12 (34%), and 10 (29%) patients reported good, some, and no improvement, respectively. Quality of life was also improved in 60% of patients. Two patients had transient stress urinary incontinence (for <6 weeks) and there were no significant long‐lasting adverse events.Conclusion: EUS BTX‐A is a valid treatment option for VD considering therapeutic options are limited. The patient must be made aware of the need for repeat treatments.